Stay updated on PROCEED Trial: Pembrolizumab Combo in Esophago-gastric Clinical Trial
Sign up to get notified when there's something new on the PROCEED Trial: Pembrolizumab Combo in Esophago-gastric Clinical Trial page.

Latest updates to the PROCEED Trial: Pembrolizumab Combo in Esophago-gastric Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedFooter shows site revision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check40 days agoChange DetectedAdministrative revision update: added v3.5.0 and removed v3.4.3.SummaryDifference0.1%

- Check47 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check75 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2; no study data or page content were modified. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check82 days agoChange DetectedThe page footer shows a revision update from v3.4.0 to v3.4.1, indicating a minor software update. No user-facing content or study details were changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check89 days agoChange DetectedShow glossary was added to the page. The page metadata now includes 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data' with a new revision tag v3.4.0 (replacing v3.3.4).SummaryDifference0.2%

Stay in the know with updates to PROCEED Trial: Pembrolizumab Combo in Esophago-gastric Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PROCEED Trial: Pembrolizumab Combo in Esophago-gastric Clinical Trial page.